As the global economy recovers in 2021 and the supply of the industrial chain improves, the Oral Peptide Drug market will undergo major changes. According to the latest research, the market size of the Oral Peptide Drug industry in 2021 will increase by USD million compared to 2020, with a growth rate of %.
The global Oral Peptide Drug industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also contains descriptions of key players, including key financial indicators and market competitive pressure analysis.
The report also assesses key opportunities in the market and outlines the factors that are and will drive the growth of the industry. Taking into account previous growth patterns, growth drivers, and current and future trends, we also forecast the overall growth of the global Oral Peptide Drug market during the next few years. The global Oral Peptide Drug market size will reach USD million in 2028, growing at a CAGR of % during the analysis period.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Peptide Drug market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Linaclotide
Insulin
Plecanatide
Cyclosporine
Octreotide
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital
Retail Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Allergan
Novo Nordisk
Synergy Pharmaceuticals ?Salix?
Novartis
Chiasma
Table of Content
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral Peptide Drug Market Size 2017-2028
2.1.2 Oral Peptide Drug Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Oral Peptide Drug Segment by Type
2.2.1 Linaclotide
2.2.2 Insulin
2.2.3 Plecanatide
2.2.4 Cyclosporine
2.2.5 Octreotide
2.3 Oral Peptide Drug Market Size by Type
2.3.1 Oral Peptide Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Oral Peptide Drug Market Size Market Share by Type (2017-2022)
2.4 Oral Peptide Drug Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.5 Oral Peptide Drug Market Size by Application
2.5.1 Oral Peptide Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Oral Peptide Drug Market Size Market Share by Application (2017-2022)
3 Oral Peptide Drug Market Size by Player
3.1 Oral Peptide Drug Market Size Market Share by Players
3.1.1 Global Oral Peptide Drug Revenue by Players (2020-2022)
3.1.2 Global Oral Peptide Drug Revenue Market Share by Players (2020-2022)
3.2 Global Oral Peptide Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Oral Peptide Drug by Regions
4.1 Oral Peptide Drug Market Size by Regions (2017-2022)
4.2 Americas Oral Peptide Drug Market Size Growth (2017-2022)
4.3 APAC Oral Peptide Drug Market Size Growth (2017-2022)
4.4 Europe Oral Peptide Drug Market Size Growth (2017-2022)
4.5 Middle East & Africa Oral Peptide Drug Market Size Growth (2017-2022)
5 Americas
5.1 Americas Oral Peptide Drug Market Size by Country (2017-2022)
5.2 Americas Oral Peptide Drug Market Size by Type (2017-2022)
5.3 Americas Oral Peptide Drug Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Peptide Drug Market Size by Region (2017-2022)
6.2 APAC Oral Peptide Drug Market Size by Type (2017-2022)
6.3 APAC Oral Peptide Drug Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Oral Peptide Drug by Country (2017-2022)
7.2 Europe Oral Peptide Drug Market Size by Type (2017-2022)
7.3 Europe Oral Peptide Drug Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral Peptide Drug by Region (2017-2022)
8.2 Middle East & Africa Oral Peptide Drug Market Size by Type (2017-2022)
8.3 Middle East & Africa Oral Peptide Drug Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Oral Peptide Drug Market Forecast
10.1 Global Oral Peptide Drug Forecast by Regions (2023-2028)
10.1.1 Global Oral Peptide Drug Forecast by Regions (2023-2028)
10.1.2 Americas Oral Peptide Drug Forecast
10.1.3 APAC Oral Peptide Drug Forecast
10.1.4 Europe Oral Peptide Drug Forecast
10.1.5 Middle East & Africa Oral Peptide Drug Forecast
10.2 Americas Oral Peptide Drug Forecast by Country (2023-2028)
10.2.1 United States Oral Peptide Drug Market Forecast
10.2.2 Canada Oral Peptide Drug Market Forecast
10.2.3 Mexico Oral Peptide Drug Market Forecast
10.2.4 Brazil Oral Peptide Drug Market Forecast
10.3 APAC Oral Peptide Drug Forecast by Region (2023-2028)
10.3.1 China Oral Peptide Drug Market Forecast
10.3.2 Japan Oral Peptide Drug Market Forecast
10.3.3 Korea Oral Peptide Drug Market Forecast
10.3.4 Southeast Asia Oral Peptide Drug Market Forecast
10.3.5 India Oral Peptide Drug Market Forecast
10.3.6 Australia Oral Peptide Drug Market Forecast
10.4 Europe Oral Peptide Drug Forecast by Country (2023-2028)
10.4.1 Germany Oral Peptide Drug Market Forecast
10.4.2 France Oral Peptide Drug Market Forecast
10.4.3 UK Oral Peptide Drug Market Forecast
10.4.4 Italy Oral Peptide Drug Market Forecast
10.4.5 Russia Oral Peptide Drug Market Forecast
10.5 Middle East & Africa Oral Peptide Drug Forecast by Region (2023-2028)
10.5.1 Egypt Oral Peptide Drug Market Forecast
10.5.2 South Africa Oral Peptide Drug Market Forecast
10.5.3 Israel Oral Peptide Drug Market Forecast
10.5.4 Turkey Oral Peptide Drug Market Forecast
10.5.5 GCC Countries Oral Peptide Drug Market Forecast
10.6 Global Oral Peptide Drug Forecast by Type (2023-2028)
10.7 Global Oral Peptide Drug Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Allergan
11.1.1 Allergan Company Information
11.1.2 Allergan Oral Peptide Drug Product Offered
11.1.3 Allergan Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Allergan Main Business Overview
11.1.5 Allergan Latest Developments
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Information
11.2.2 Novo Nordisk Oral Peptide Drug Product Offered
11.2.3 Novo Nordisk Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Novo Nordisk Main Business Overview
11.2.5 Novo Nordisk Latest Developments
11.3 Synergy Pharmaceuticals ?Salix?
11.3.1 Synergy Pharmaceuticals ?Salix? Company Information
11.3.2 Synergy Pharmaceuticals ?Salix? Oral Peptide Drug Product Offered
11.3.3 Synergy Pharmaceuticals ?Salix? Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Synergy Pharmaceuticals ?Salix? Main Business Overview
11.3.5 Synergy Pharmaceuticals ?Salix? Latest Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Oral Peptide Drug Product Offered
11.4.3 Novartis Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Novartis Main Business Overview
11.4.5 Novartis Latest Developments
11.5 Chiasma
11.5.1 Chiasma Company Information
11.5.2 Chiasma Oral Peptide Drug Product Offered
11.5.3 Chiasma Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Chiasma Main Business Overview
11.5.5 Chiasma Latest Developments
12 Research Findings and Conclusion
Allergan
Novo Nordisk
Synergy Pharmaceuticals ?Salix?
Novartis
Chiasma
*If Applicable.